Complete if Known
`
`Art Unit
`Confirmation Number
`
`DocumentNo.
`
`U.S. PATENT DOCUMENTS
`
`Examiner
`Initials*
`
`Cite
`No."
`
`Number— Kind Code?(if
`known)
`
`Publication Date
`MM-DD-YYYY
`
`Nameof Patentee or
`Applicant of Cited Document
`
`Lotvall et al.
`04-25-2017
`US-9,629,929
`Lotvall et al.
`07-21-2015
`US-9,085,778
`Finkelet al.
`07-29-2008
`US-7,405,292
`Abrignani et al.
`04-03-2007
`US-7,198,923
`
`AS_|US-6,812,023 11-02-2004 Lamparskietal.
`
`US-2007/0298118 A1
`12-27-2007
`Lotvall et al.
`
`A2_|
`A3_|
`
`INFORMATION DISCLOSURE i
`STATEMENT BY APPLICANT
`ea
`(Not for submission under 37 CFR 1.99)
`-
`-
`-
`Codiak BioSciences,Inc.
`Not yet known
`9412
`Notyet known
`
`Attorney Docket Number|32724-42179/US
`
`
`
`
`here if English languagetranslation is attached.
`
` |ssa|wo 03/044166
`
`
`oa
`
`Delcayreet al.
`10-07-2004
`_US-2004/0197314 A1
`A7_|
`
`A8|US-2004/0028692 A1 02-12-2004 Zitvogel et al.
`
`
`PF Foreign Patent Document
`Examiner
`Country Code* — Number*
`Initials*
`Kind Code(if known)
`
`.
`
`FOREIGN PATENT DOCUMENTS
`
`Publication
`Date
`MM-DD-
`YYYY
`
`Name of Patentee or
`Applicant of Cited Document
`
`CN 1325441
`
`12-05-2001
`
`
`
`[|woos11330[02-13-2003|AdamOpelAGCid
`
`02-27-2003
`WO 03/016522
`05-30-2003_|The Regents Of The University Of California
`
`
`B10| WO 2005/121369 12-22-2005|Sourcephamm, Inc
`
`11 10-21-2010_|Isis Innovation LimitedWO 2010/119256
`
`
`EXAMINER SIGNATURE
`
`[ExaminerSignature
`Date Considered pT
`*EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609. Drawline through
`a citation if not in conformance and notconsidered. Include copy of this form with next communication to applicant.
`
`1Applicant’s unique citation designation number (option). 2? See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ? Enter office
`that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the
`Emperor must precede the serial number of the patent document.
`5 Kind of documentby the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. © Applicant is to place a check mark
`
`

`

`Attorney Docket Number|32724-42179/US
`
`INFORMATION DISCLOSURE i
`STATEMENT BY APPLICANT
`ea
`(Not for submission under 37 CFR 1.99)
`-
`-
`-
`Codiak BioSciences,Inc.
`Not yet known
`9412
`Notyet known
`
`Complete if Known
`
`Art Unit
`Confirmation Number
`
`OTHER REFERENCES- NON-PATENT LITERATURE DOCUMENTS
`
`Examiner|Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item
`Initials*
`No."
`(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),
`TS
`publisher, city and/or country where published
`c1|CHAPUT, N. et al., “The potential of exosomesin immunotherapy,” Expert Opinion in Biological Therapy,
`2005, Vol. 5, No. 6, pp. 737-747.
`c2|ADMYRE, C. et al., Abstract of “Exosomes with Major Histocompatibility Complex Class II and Co-
`Stimulatory Molecules are Present in Human BALFluid,” Eur. Respir. J., October 2003, Vol. 4, pp. 578-583
`c3|ALVAREZ-ERVITI, L. et al., “Delivery of sIRNA to the Mouse Brain by Systemic Injection of Targeted
`Exosomes,” Nature Biotechnology, April 2011, Vol. 29, No. 4., pp. 341-347.
`c4|BAJ-KRZYWORZEKA,M. et al., "Tumour-derived microvesicles carry several surface determinants and
`mRNAof tumour cells and transfer some of these determinants to monocytes," Cancer Immunol.
`Immunother., 2006, Vol. 55., pp. 808-818.
`c5|BELOV,L. et al., “Extensive surface protein profiles of extracellular vesicles from cancercells may provide
`diagnostic signatures from blood samples,” Journal of Extracellular Vesicles, 2016, Vol. 5, pp. 1-12.
`c6|COUZIN, J., et al., "The ins and outs of exosomes", Science, 2005, Vol. 308, pp. 1862-1863.
`c7|DELCAYRE, A.etal., "Exosomesas novel therapeutic nanodevices," Current Opinion in Molecular
`Therapeutics, 2006, Vol. 8, No. 1, pp. 31-38.
`cg|“Deliverx™ and DeliverX Plus siRNA Transfection Kits: User Manual,” Panomics, Inc., 2003, 20 pages.
`cg|ELANDALOUSSI, S. et al., “Exosomes for Targeted siRNA Delivery Across Biological Barriers,” Advanced
`Drug Delivery Reviews, 2013, Vol. 65, pp. 391-397.
`ELDH, M. et al., “Exosomes communication protective messages during oxidative stress; possible role of
`exosomal shuttle RNA,” PLOS one, December 2010, Vol. 5, Issue 12: €15353, pp. 1-8.
`ESCOLA,J.M. et al., Abstract of “Selective Enrichment of Tetraspan Proteins on the Internal Vesicles of
`Multivesicular Endosomes and on Exosomes Secreted by Human B-Lymphocytes,” J. Biol. Chem., August
`1998, Vol. 273, No. 32, pp. 20121-20127.
`c12| European Communication dated Jul. 6, 2011 issued in European Patent Application No. 07 748 459.0, 5
`pages.
`C13 European Communication dated Jun. 17, 2013 issued in European Patent Application No. 07 748 459.0, 3
`pages.
`
`c19|
`
`c11|
`
`c14| European Communication dated Jun. 27, 2012 issued in European Patent Application No. 07 748 459.0, 4
`pages.
`c15| European Examination Report and Supplemental Search Report dated Oct. 8, 2010 issued in European
`Patent Application No. 07 748 459.0, 7 pages.
`c16| European Examination Report, European Application No. 15158949.6, dated Jun. 2, 2017, 4 pages.
`C17|European Examination Report, European Application No. 15158949.6, dated Jun. 7, 2016, 4 pages.
`C18|European Examination Report, European Application No. 15158949.6, dated Oct. 19, 2016, 6 pages.
`
`here if English languagetranslation is attached.
`
`EXAMINER SIGNATURE
`Examiner Signature pt
`Date Considered pT
`*EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609. Drawline through
`a citation if not in conformance and notconsidered. Include copy of this form with next communication to applicant.
`
`1Applicant’s unique citation designation number (option). 2? See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ? Enter office
`that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the
`Emperor must precede the serial number of the patent document.
`5 Kind of documentby the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. © Applicant is to place a check mark
`
`
`
`
`
`
`
`

`

`Attorney Docket Number|32724-42179/US
`
`INFORMATION DISCLOSURE i
`STATEMENT BY APPLICANT
`ea
`(Not for submission under 37 CFR 1.99)
`-
`-
`-
`Codiak BioSciences,Inc.
`Not yet known
`9412
`Notyet known
`
`Complete if Known
`
`Art Unit
`Confirmation Number
`
`OTHER REFERENCES- NON-PATENT LITERATURE DOCUMENTS
`
`Examiner|Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item
`Initials*
`No.!
`(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),
`Te
`publisher, city and/or country where published
`C19] European Examination Report, European Application No. 15158949.6, March 13, 2018, 3 pages.
`C20|European Extended Search Report, European Application No. 07748459.0, dated Oct. 18, 2010, 8 pages.
`C21|European Extended Search Report, European Application No. 15158949.6, dated Jul. 13, 2015, 9 pages.
`C22| European Extended Search Report, European Application No. 18158203.2, dated Aug. 21, 2018, 12 pages.
`C23|European Summons to Attend Oral Proceedings Pursuant to Rule 115(1) EPC, European Application No.
`07748459.0, dated Apr. 24, 2014, 7 pages.
`c24| GEHL,J., "Electroporation: theory and methods, perspectives for drug delivery, gene therapy and research,"
`Acta Physiol Scand, 2003, Vol. 177, pp. 437-447.
`C25 LASSER,C., “Exosomesin Diagnostic and Therapeutic Applications: Biomarker, Vaccine and RNA
`Interference Delivery Vehicle,” Expert Opinion on Biological Therapy, 2015, Vol. 15, No. 1, pp. 103-117.
`c26|LEDERBERG, J., "The transformation of genetics by DNA: An anniversary celebration of Avery, MacLeod
`and McCarty (1944)," Genetics, Feb. 1994, Vol. 136, No. 2., pp. 423-426.
`LENER, T.et al., “Applying Extracellular Vesicles Based Therapeutics in Clinical Trials — an ISEV Position
`Paper,” Journal of Extracellular Vesicles, 2015, pp. 1-31, Vol. 4: 30087.
`LIN, XP. et al., Abstract of “Human Small Intestinal Epithelial Cells Constitutively Express the Key Elements
`for Antigen Processing and the Production for Exosomes,” Blood Cells Mol. Dis., Sep-Oct. 2005, pp. 122-
`128, Vol. 35, No. 2.
`LOTVALL,J. et al., “Cell to Cell Signaling Via Exosomes Through esRNA,”Cell Adhesion & Migration,
`July/August/September 2007, pp. 156-158, Vol. 1, No. 3.
`c30|LOTVALL,J. et al., “Minimal Experimental Requirements for Definition of Extracellular Vesicles and Their
`Functions: A Position Statement from the International Society for Extracellular Vesicles,” Journal of
`Extracellular Vesicles, 2014, pp. 1-6, Vol. 3: 26913.
`LUO, ZB. et al., "Immunotherapy of dendritic cells and its exosomes transfected with mRNAofgastric
`cancer cells in tumor-carried mice," 2004, World Chin. J. Digestol., Jan. 2004, Vol. 12, No. 1, pp. 9-12.
`C32| OHNO, S. et al., “systemically Injected Exosomes Targeted to EGFR Deliver Antitumor MicroRNAto Breast
`Cancer Cells,” Molecular Therapy, January 2013, Vol. 21, No. 1, pp. 185-191.
`C33|PCT Written Opinion, PCT Application No. PCT/SE2007/050298, dated Sep. 14, 2007, 9 pages.
`c34|
`PONSAERTS, P. et al., "Editorial: Modulation of cellular behavior by exogenous messenger RNA,"
`Leukemia, 2006, Vol. 20, pp. 767-769.
`c35|RAPOSO, G. et al., "B lymphocytes secrete antigen-presenting vesicles," J. Exp. Med., Mar. 1996, Vol. 183,
`pp. 1161-1172.
`c36|RATAJCZAK,J. et al., "Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors:
`evidence for horizontal transfer of mRNA andprotein delivery", Leukemia, 2006, Vol. 20, pp. 847-856.
`c37| RAZIN, E. et al., "Interleukin 3: a differentiation and growth factor for the mouse mastcell that contains
`chondroitin sulfate e proteoglycan", The Journal of Immunology, Mar. 1984, Vol. 132, No. 3, pp. 1479-1486.
`
`
`
`
`
`
`
`C27|
`
`c28|
`
`c29|
`
`c31|
`
`here if English languagetranslation is attached.
`
`EXAMINER SIGNATURE
`Examiner Signature pt
`Date Considered pT
`*EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609. Drawline through
`a citation if not in conformance and notconsidered. Include copy of this form with next communication to applicant.
`
`1Applicant’s unique citation designation number (option). 2? See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ? Enter office
`that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the
`Emperor must precede the serial number of the patent document.
`5 Kind of documentby the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. © Applicant is to place a check mark
`
`

`

`Attorney Docket Number|32724-42179/US
`
`INFORMATION DISCLOSURE i
`STATEMENT BY APPLICANT
`ea
`(Not for submission under 37 CFR 1.99)
`-
`-
`-
`Codiak BioSciences,Inc.
`Not yet known
`9412
`Notyet known
`
`Complete if Known
`
`Art Unit
`Confirmation Number
`
`x
`
`x
`
`x
`
`
`
`
`
`OTHER REFERENCES- NON-PATENT LITERATURE DOCUMENTS
`
`Examiner|Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item
`Initials*
`No.!
`(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),
`Te
`publisher, city and/or country where published
`SHURTLEFF, M.J. et al., “A Broad Role for YBX1 in Defining the Small Non-Coding RNA Composition of
`Exosomes,” bioRxiv Preprint First Posted July 7, 2017, 42 pages.
`SIMPSON, R.J. ET AL., "Extracellular Microvesicles: The Need for Internationally Recognised Nomenclature
`and Stringent Purification Criteria," Proteomics & Bioinformatics, 2012, Vol. 5, No. 2, 1 page.
`STOORVOGEL,W.et al., "The Biogenesis and Functions of Exosomes,"Traffic, February 2002, Vol. 3, No.
`5, pp. 321-330.
`The State Intellectual Property Office of the People’s Republic of China, Office Action, Chinese Application
`No. 201511027801.8, December 7, 2016, 21 pages.
`C42| The State Intellectual Property Office of the People’s Republic of China, Office Action, Chinese Application
`No. 2007800154690, October 30, 2012.
`c43| The State Intellectual Property Office of the People’s Republic of China, Office Action, Chinese Application
`No. 201511027801.8, April 23, 2018, 19 pages.
`c44| The State Intellectual Property Office of the People’s Republic of China, Office Action, Chinese Application
`No. 201511027801.8, June 13, 2017, 22 pages.
`c45| The State Intellectual Property Office of the People’s Republic of China, Office Action, Chinese Application
`No. 201511027801.8, December 22, 2017, 20 pages.
`c4g|THERY,C. et al., "Exosomes: composition, biogenesis and function," Nature Reviews Immunology, August
`2002, pp. 569 - 579.
`C47|United States Office Action, U.S. Application No, 11/799,148, September 3, 2009, 6 pages.
`C48|United States Office Action, U.S. Application No. 11/799,148, April 2, 2010, 8 pages.
`c49| United States Office Action, U.S. Application No. 11/799,148, December 17, 2010, 3 pages.
`C50|United States Office Action, U.S. Application No. 11/799,148, March 26, 2014, 12 pages.
`C51|United States Office Action, U.S. Application No. 11/799,148, November 7, 2014, 13 pages.
`C52| United States Office Action, U.S. Application No. 11/799,148, September 29, 2010, 7 pages.
`C53 United States Office Action, U.S. Application No. 14/750,457, November3, 2016, 13 pages.
`C54|United States Office Action, U.S. Application No. 15/476,844, October 19, 2017, 14 pages.
`C55|United States Office Action, U.S. Application No. 14/750,457, March 25, 2016, 9 pages.
`c56| VALADI, H. et al., "Exosome-mediated transfer of mRNAs and microRNAsis a novel mechanism of genetic
`exchange betweencells," Nature Cell Biology, Jun. 2007, Vol. 9, No. 6, pp. 654-659.
`c57| VAN DER POLL,E. et al., “Classification, Functions, and Clinical Relevance of Extracellular Vesicles,”
`Pharmacological Reviews, 2012, Vol. 64, No. 3, pp. 676-705.
`c58| WAHLGREN, J. et al., "Plasma exosomescan deliver exogenous short interfering RNA to monocytes and
`lymphocytes," Nucleic Acids Research, 2012, Vol. 40, No. 17, 12 pages.
`
`c38|
`
`c39|
`
`c49|
`
`c41|
`
`
`
`EXAMINER SIGNATURE
`
`[ExaminerSignature
`Date Considered pT
`*EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609. Drawline through
`a citation if not in conformance and notconsidered. Include copy of this form with next communication to applicant.
`
`1Applicant’s unique citation designation number (option). 2? See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ? Enter office
`that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the
`Emperor must precede the serial number of the patent document.
`5 Kind of documentby the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. © Applicant is to place a check mark
`
`here if English languagetranslation is attached.
`
`

`

`Complete if Known
`ApplicationNumber|16/201,937_
`INFORMATION DISCLOSURE i
`STATEMENTBY APPLICANT
`janLOTVALL
`(Not for submission under 37 CFR 1.99)
`an
`VE
`Codiak BioSciences, Inc.
`
`9412
`
`September/October 2010, Vol. 3, No. 5, pp. 447-450.
`
`Attorney Docket Number|32724-42179/US
`
`OTHER REFERENCES- NON-PATENT LITERATURE DOCUMENTS
`
`Examiner|Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item
`Initials*
`No.!
`(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),
`publisher, city and/or country where published
`c59| YEO, R.W.Y.et al, “Mesenchymal Stem Cell: An Efficient Mass Producer of Exosomesfor Drug Delivery,”
`Advanced Drug Delivery Reviews, 2013, Vol. 65, pp. 336-341.
`ceo|ZOMER, A. et al., “Exosomes: Fit to Deliver Small RNA,” Communicative & Integrative Biology,
`
`EXAMINER SIGNATURE
`
`[ExaminerSignature
`Date Considered pT
`*EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609. Drawline through
`a citation if not in conformance and notconsidered. Include copy of this form with next communication to applicant.
`
`here if English languagetranslation is attached.
`
`1Applicant’s unique citation designation number (option). 2? See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ? Enter office
`that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the
`Emperor must precede the serial number of the patent document.
`5 Kind of documentby the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. © Applicant is to place a check mark
`
`

`

`Complete if Known
`ApplicationNumber|16/201,937_
`INFORMATION DISCLOSURE i
`STATEMENTBY APPLICANT
`janLOTVALL
`(Not for submission under 37 CFR 1.99)
`an
`VE
`Codiak BioSciences, Inc.
`
`9412
`
`Attorney Docket Number|32724-42179/US
`
`Please see 37 CFR 1.97 and 1.98 to makethe appropriate selection(s):
`
`CERTIFICATION STATEMENT
`
`That each item of information contained in the information disclosure statementwas first cited in any communication
`[-]
`from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
`information disclosure statement. See 37 CFR 1.97(e)(1).
`
`OR
`
`48,006
`
`That no item of information contained in the information disclosure statement was cited in a communication from a
`[-]
`foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after
`making reasonable inquiry, no item of information contained in the information disclosure statement was known to any
`individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement.
`See 37 CFR 1.97(e)(2).
`
`This application relies, under 35 U.S.C. § 120, on the earlierfiling date of prior application No. 15/857,539, filed
`xX]
`December 28, 2017, No. 15/476,844, filed March 31, 2017, No. 14/750,457, filed June 25, 2015, and No. 11/799,148,filed
`April 30, 2017, and the references B1-B11 and C1-C60 cited therein are hereby referenced, but are not required to be provided
`in this application under 37 CFR § 1.98(d).
`
`[]
`
`[]
`
`See attached certification statement.
`
`The feesetforth in 37 CFR 1.17 (p) has been submitted herewith.
`
`xX]
`
`A certification statement is not submitted herewith.
`
`SIGNATURE
`
`A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see
`CFR 1.4(d) for the form of the signature.
`
`Signature
`
`/Chris Ullsperger/
`
`Date (YYYY-MM-DD)
`
`November 29, 2018
`
`Name/Print
`
`Chris J. Ullsperger
`
`Registration Number
`
`